Clinical Trial Update: Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating safety and biological activity of C2L-OCT-01 PR in acromegaly was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acromegaly

Drugs mentioned

• C2L-OCT-01 PR

Snippet

Sponsor: Ambrilia Biopharma, Inc. | Conditions: Acromegaly | Phase 3 | Status: TERMINATED